245 related articles for article (PubMed ID: 25603482)
1. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
[TBL] [Abstract][Full Text] [Related]
2. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
3. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
4. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
Blake JF; Burkard M; Chan J; Chen H; Chou KJ; Diaz D; Dudley DA; Gaudino JJ; Gould SE; Grina J; Hunsaker T; Liu L; Martinson M; Moreno D; Mueller L; Orr C; Pacheco P; Qin A; Rasor K; Ren L; Robarge K; Shahidi-Latham S; Stults J; Sullivan F; Wang W; Yin J; Zhou A; Belvin M; Merchant M; Moffat J; Schwarz JB
J Med Chem; 2016 Jun; 59(12):5650-60. PubMed ID: 27227380
[TBL] [Abstract][Full Text] [Related]
5. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619
[TBL] [Abstract][Full Text] [Related]
6. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
7. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Velaparthi U; Wittman M; Liu P; Carboni JM; Lee FY; Attar R; Balimane P; Clarke W; Sinz MW; Hurlburt W; Patel K; Discenza L; Kim S; Gottardis M; Greer A; Li A; Saulnier M; Yang Z; Zimmermann K; Trainor G; Vyas D
J Med Chem; 2008 Oct; 51(19):5897-900. PubMed ID: 18763755
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
9. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
Boga SB; Alhassan AB; Cooper AB; Doll R; Shih NY; Shipps G; Deng Y; Zhu H; Nan Y; Sun R; Zhu L; Desai J; Patel M; Muppalla K; Gao X; Wang J; Yao X; Kelly J; Gudipati S; Paliwal S; Tsui HC; Wang T; Sherborne B; Xiao L; Hruza A; Buevich A; Zhang LK; Hesk D; Samatar AA; Carr D; Long B; Black S; Dayananth P; Windsor W; Kirschmeier P; Bishop R
Bioorg Med Chem Lett; 2018 Jun; 28(11):2029-2034. PubMed ID: 29748051
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.
Mallinger A; Crumpler S; Pichowicz M; Waalboer D; Stubbs M; Adeniji-Popoola O; Wood B; Smith E; Thai C; Henley AT; Georgi K; Court W; Hobbs S; Box G; Ortiz-Ruiz MJ; Valenti M; De Haven Brandon A; TePoele R; Leuthner B; Workman P; Aherne W; Poeschke O; Dale T; Wienke D; Esdar C; Rohdich F; Raynaud F; Clarke PA; Eccles SA; Stieber F; Schiemann K; Blagg J
J Med Chem; 2015 Feb; 58(4):1717-35. PubMed ID: 25680029
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.
Pettus LH; Andrews KL; Booker SK; Chen J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS; Wang HL
J Med Chem; 2016 Jul; 59(13):6407-30. PubMed ID: 27285051
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel orally bioavailable GPR40 agonists.
Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.
Goldstein DM; Soth M; Gabriel T; Dewdney N; Kuglstatter A; Arzeno H; Chen J; Bingenheimer W; Dalrymple SA; Dunn J; Farrell R; Frauchiger S; La Fargue J; Ghate M; Graves B; Hill RJ; Li F; Litman R; Loe B; McIntosh J; McWeeney D; Papp E; Park J; Reese HF; Roberts RT; Rotstein D; San Pablo B; Sarma K; Stahl M; Sung ML; Suttman RT; Sjogren EB; Tan Y; Trejo A; Welch M; Weller P; Wong BR; Zecic H
J Med Chem; 2011 Apr; 54(7):2255-65. PubMed ID: 21375264
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Schroeder GM; An Y; Cai ZW; Chen XT; Clark C; Cornelius LA; Dai J; Gullo-Brown J; Gupta A; Henley B; Hunt JT; Jeyaseelan R; Kamath A; Kim K; Lippy J; Lombardo LJ; Manne V; Oppenheimer S; Sack JS; Schmidt RJ; Shen G; Stefanski K; Tokarski JS; Trainor GL; Wautlet BS; Wei D; Williams DK; Zhang Y; Zhang Y; Fargnoli J; Borzilleri RM
J Med Chem; 2009 Mar; 52(5):1251-4. PubMed ID: 19260711
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
Degorce SL; Barlaam B; Cadogan E; Dishington A; Ducray R; Glossop SC; Hassall LA; Lach F; Lau A; McGuire TM; Nowak T; Ouvry G; Pike KG; Thomason AG
J Med Chem; 2016 Jul; 59(13):6281-92. PubMed ID: 27259031
[TBL] [Abstract][Full Text] [Related]
18. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
[TBL] [Abstract][Full Text] [Related]
19. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
20. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
